Graft Polymer (UK) PLC (LSE:GPL) has announced that its partner, Awakn Life Sciences, has entered into a research agreement with the University of Nottingham.
The study will explore a new chemical compound co-developed by both companies, aiming to improve social cognition and pro-social behaviours— key factors in treating mental health conditions such as post-traumatic stress disorder (PTSD).
Led by Dr Madeleine King, an expert in behavioural neuroscience, the research will test the compound in rodent models using the social transmission of food preferences method.
The study, expected to conclude by the end of 2024, marks a crucial step in developing new treatments for trauma-related disorders.
This project is part of Graft Polymer's ongoing efforts to create innovative therapies for mental health, addressing a condition that affects millions across the globe.
"This is a significant step forward in our joint programme with Awakn," said Graft CEO Anthony Tennyson.
"The in vivo testing at the University of Nottingham will be pivotal in assessing the therapeutic potential of our novel aminoindane compounds, bringing us closer to addressing the unmet needs in trauma-related mental health disorders."